ORPHA:2911
Poland syndrome
Also known as: Poland anomaly · Poland sequence
Publications
1,346
84th percentile
Trials
1
Interventional, condition-specific
Researchers
1,006
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare characterized by a unilateral, complete or partial, absence of the pectoralis major (and often minor) muscle, ipsilateral breast and nipple anomalies, hypoplasia of the pectoral subcutaneous tissue, absence of pectoral and axillary hair, and possibly accompanied by chest wall and/or upper limb defects.
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008262
- MeSH:D011045
- OMIM:173800
- UMLS:C0032357
- NCIT:C85017
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,346 matched papers (544 in last 10 years) Source
- Phenotype characterisedPresent
73 HPO annotations (e.g. Unilateral absence of pectoralis major muscle; Short ribs; Unilateral brachydactyly) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
73
Associated phenotypes · MONDO:0008262
- Unilateral absence of pectoralis major muscle
- Short ribs
- Unilateral brachydactyly
- Rib fusion
- Hypoplasia of serratus anterior muscle
Showing 5 of 73 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
1 associated chemical. Therapeutic evidence is listed first when present — not a treatment recommendation.
- Cocaine · marker/mechanism
Literature
Is anyone studying this?
1,346
1,346 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,346 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
544 in the last 10 years · medium confidence · 84th percentile (publications denominator)
Phrase hits: 1,346 · MeSH hits: 0
Who's working on it?
1,006
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Baldelli I3 papers · 2025
Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Viale Benedetto XV, 6, 2nd Floor, 16132, Genoa, Italy.
Papers in Europe PMC - 02Delay E3 papers · 2024
Unité de chirurgie plastique et reconstructrice (Dr E Delay), centre Léon-Bérard, 28, rue Laënnec, 69373 Lyon cedex 08, France; Cabinet, 50, rue de la République, 69002 Lyon, France. Electronic address: emmanuel.delay@lyon.unicancer.fr.
Papers in Europe PMC - 03Campbell S2 papers · 2026
Department of Thoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland
Papers in Europe PMC - 04Chen Y2 papers · 2026
Department of General Surgery, the First Medical Center of the Chinese PLA General Hospital, Beijing, China.
Papers in Europe PMC - 05Chitayat D2 papers · 2024
Division of Clinical and Metabolic Genetics, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada.
Papers in Europe PMC - 06Cho SY2 papers · 2025
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Papers in Europe PMC - 07Chung JH2 papers · 2022
Department of Plastic Surgery, Korea University College of Medicine, Seoul, South Korea.
Papers in Europe PMC - 08Doyle R2 papers · 2026
Department of Thoracic Surgery, Mater Misericordiae University Hospital, Dublin, Ireland
Papers in Europe PMC - 09Forlini V2 papers · 2025
From the Department of Pediatric Surgery, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Papers in Europe PMC - 10Frobert P2 papers · 2024
Unité de chirurgie plastique et reconstructrice, Centre Léon Bérard, 28, rue Laënnec, 69373 Lyon cedex 08, France.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
medium confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06146231·RECRUITING·Motiva Flora® Aesthetic Breast Recon® Clinical Study
Not reviewed·Conditions: Mammaplasty · Breast Cancer · Poland Syndrome·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 74 · after dedupe 73 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 73 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (73)
- isrctn·ISRCTN34498249·Recruiting·A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3-stage metabolic dysfunction-associated steatohepatitis (BOS-580-302)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17213765·No longer recruiting·A study comparing two minimally invasive injection-based treatments for lumbar disc herniation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14934633·Recruiting·Validation of clinical tests used in physiotherapy diagnostics
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96046168·No longer recruiting·Fascial manipulation and thoracolumbar pain
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN39379437·Recruiting·A study of guselkumab versus risankizumab in participants with moderately to severely active Crohn's Disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15146958·Recruiting·A study of nipocalimab in adults with moderate to severe systemic lupus erythematosus
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15332421·No longer recruiting·The influence of a prehabilitation on the health of lung cancer patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10469053·Recruiting·Using light-based imaging to make heart stent treatment safer and more effective
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17936325·Recruiting·Phase III study of daraxonrasib (RMC-6236) in previously treated NSCLC patients with RAS mutations
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15911581·Recruiting·A Study of Icotrokinra in participants with moderately to severely active Crohn's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21855023·Recruiting·A phase 3 randomized double-blinded, placebo-controlled study of JNJ-78278343, T-Cell redirecting agent targeting Human Kallikrein 2 with best supportive care (BSC) versus placebo with BSC for metastatic castration-resistant prostate cancer_KLK2 comPAS_78278343PCR3001
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37340032·Recruiting·A study of bleximenib, venetoclax and azacitidine for treatment of participants with newly diagnosed acute myeloid leukemia (cAMeLot-2)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10844715·No longer recruiting·The effect of sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16484644·No longer recruiting·The effects of dry needling on patients with muscle pain
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82669637·No longer recruiting·Prognostic value of excessive perineal descent for the surgical outcome of obstructed defecation syndrome
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14534389·Recruiting·Nipocalimab in moderate to severe Sjogren's disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16256551·No longer recruiting·Effects of probiotic supplementation on gut health, food tolerance and athletic performance of non-elite endurance athletes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN56244307·No longer recruiting·A study to assess the safety and efficacy of a gel treatment in subjects with acne vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49040930·No longer recruiting·A long-term study to assess the safety and efficacy of a gel treatment in subjects with Acne Vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17841362·Recruiting·A study of nipocalimab or intravenous immunoglobulin in pregnancies at risk of fetal and neonatal alloimmune thrombocytopaenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15814719·No longer recruiting·A study in healthy volunteers to look at the safety and tolerability of the test medicine VS-041 and how it is taken up by the body when given as single and multiple doses
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN46766641·No longer recruiting·A Phase I randomized, open-label pharmacokinetic comparability study comparing pre- and post-change teclistamab in participants with relapsed/refractory multiple myeloma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79155276·No longer recruiting·A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN98745687·No longer recruiting·A Phase Ib/II, open-label study of amivantamab monotherapy and amivantamab in addition to other therapeutic agents in participants with head and neck squamous cell carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79102999·No longer recruiting·A Phase III study of sepiapterin versus sapropterin in participants with phenylketonuria ≥2 years of age
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Poland syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Poland syndrome" OR "Poland anomaly" OR "Poland sequence"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Poland syndrome" OR "Poland anomaly" OR "Poland sequence"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T21:39:16.514Z
